Revolution Medicines hires Mirati, ALX vet Sandler

Revolution Medicines Inc. (NASDAQ:RVMD) hired Alan Sandler as chief development officer, a newly created role at the oncology company, and appointed a pair of regional GMs. Sandler joins from ALX Oncology Holdings Inc. (NASDAQ:ALXO), where he was CMO. Before that, he was EVP and CMO at Mirati Therapeutics Inc. through its acquisition by Bristol Myers Squibb Co. (NYSE:BMY). The biotech also named Alicia Gardner SVP, GM for the U.S., and Gerwin Winter as SVP, GM for Europe.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) hired Eric Olson as EVP and CBO, following the planned retirement of Thomas Kassberg after 14 years at the rare disease company. Olson was CBO at Stoke Therapeutics Inc. (NASDAQ:STOK), where he led the biotech’s partnership with Biogen Inc. (NASDAQ:BIIB) for Dravet therapy zorevunersen. Prior to that, he was VP, head of business development at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)...